produced a similar inhibitory effect to that of the drug combination on CML CD34
þ cell viability. 6 However, LMB also inhibited the proliferation of BCR-ABL À CD34 þ cells by three-to fivefold, showing a cytostatic effect with recovery 3 days after drug washout, demonstrating the non-specific toxicity of this drug (Figure 1e ). This result suggests that CML CD34 þ cells seem to be more sensitive to inhibition of nuclear export than BCR-ABL À CD34 þ cells. The recovery of both CML and non-CML cells after drug washout could be explained by the de novo synthesis of CRM1, which reversed the LMB effect. 7 As anticipated, Ph þ CD34 þ cells were less sensitive than K562 cells to IM exposure, showing the persistence/resistance of these stem and progenitor cells in the presence of IM. IM led to a non-significant reduction in the viable Ph À CD34 þ population (20%) (P40.05) after both 3-day exposure and 13 days after drug washout (40%) (P40.05), corroborating an earlier report in which exposure (3 days) to 10 mM IM did not significantly reduce the expansion of Ph À CD34 þ cells. 8 Furthermore, as the combination treatment failed to eliminate the total CML CD34 þ cells, its effect on the more primitive quiescent leukaemic stem cells (CD34 þ 38 À or equivalent) was not investigated.
In conclusion, our results indicate that even the manipulation of the cellular localization of BCR-ABL is not sufficient to induce cell death of all the Ph þ CD34 þ cell population. It is possible that the combination of IM and LMB would be more effective if a selective inhibitor of the ABL nuclear export signal were available. Myeloproliferative neoplasms (MPNs) have been associated with high incidence of thrombosis and bleeding episodes, which significantly contribute to disease-related morbidity and mortality. 1 Notably, clinical data indicate an association of the JAK2 V617F mutation, seen in nearly all polycythemia vera cases and half of those with essential thrombocythemia with erythrocytosis, leukocytosis and thrombotic complications. Particularly for essential thrombocythemia, a recent overview has suggested that the JAK2 V617F positivity may be associated with an increased risk of thrombosis, an effect mediated by the leukocytosis conferred by the mutation. 2 Several studies have indicated that a substantial proportion of patients with idiopathic Budd-Chiari syndrome, portal vein or mesenteric vein thrombosis carry the JAK2 V617F mutation, even in the absence of overt clinical or hematological features of an MPN. 3 Detection of JAK2 V617F mutation in this setting is a marker of a 'latent' MPN as positive patients appear to have bone marrow histological features characteristic of MPN. 3, 4 Recently, Mercier et al. screened 27 patients aged o40 years, who had experienced an acute myocardial infarction (AMI). Three out of 27 (11.1%) patients carried the JAK2 V617F mutation, leading the authors to conclude that a latent MPN may often be present in this group of patients, warranting screening for the V617F mutation. 5 In contrast, in a study of 28 patients with AMI at a young age (defined as o50 years), none was found to harbour the JAK2 V617F mutation. That group of patients was part of a larger cohort of patients with arterial or venous thrombosis outside the splanchnic circulation. The study suggested that screening for JAK2 V617F mutation is not warranted as part of the hypercoagulable work-up in patients with non-splanchnic thrombosis. 6 We investigated the prevalence of the JAK2 V617F mutation in a prospectively assembled cohort of AMI patients aged o35 years. We hypothesized that JAK2 V617F may be further enriched in this group of patients as it represents a good model because the mainly genetic factors, and to a lesser extent the environmental factors, have an impact on the pathogenesis of the thrombosis. We studied consecutive patients admitted to our institution between January 1998 and December 2005 who had suffered their first AMI under the age of 35 years. DNA was extracted from peripheral blood samples by standard procedures after isolation of total leukocytes following red-cell lysis. The JAK2 V617F mutation was detected using a tetra-primer amplification refractory mutation system (ARMS) polymerase chain reaction (PCR) assay with a sensitivity of 1%. 7 The observed incidence of JAK2 V617F mutated cases was compared with the incidence of 5% using the Clopper-Pearson exact test. Statistical analysis was performed using STATA, version SE/10 (STATA Corp, College Station, TX). Significance was defined as P-value o0.05; P-values were two-tailed. 8 The study was approved by the internal review boards from all the participating institutes and written informed consent was obtained from all patients according to the Declaration of Helsinki.
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We enrolled 147 patients (125 male and 22 female) with no evidence of an underlying MPN who had suffered an AMI under the age of 35 years. Detailed clinical information was available for 135 (92%) cases: the mean age was 32 years (s.d., 3 years), all were on standard post-AMI treatment (b-blockers, angiotensinconverting enzyme inhibitors, antiplatelets and statins) and 30 (22.2%) suffered a second acute coronary event during followup. The JAK2 V617F mutation was not detected in any case, yielding a 95% confidence interval for the prevalence of the mutation ranging from 0 to 2.48% and excluding a 5% prevalence of JAK2 V617F in this population (P ¼ 0.001). On the basis of this large cohort of young patients with AMI, our findings indicate that a latent JAK2 V617F-positive MPN is an unlikely cause of coronary arterial thrombosis that leads to AMI, although we cannot exclude the possibility of a small, significant excess of JAK2 V617F over background levels. Thus, our findings reinforce the suggestion that screening for the JAK2 V617F mutation may not be warranted for all patients with unexplained thrombosis and should probably be restricted to those who present with splanchnic venous thrombosis and those with non-splanchnic thrombosis associated with clinical or laboratory findings suggestive of an MPN diagnosis. Corticosteroid therapy has been a long-standing component in the treatment of multiple myeloma, in which it is believed to reduce monoclonal protein levels and increase chemotherapeutic response. Earlier, high doses of dexamethasone were empirically chosen, given the paucity of specific trial data to guide optimal dosing. However, with the advent of agents with increasing activity in multiple myeloma, such as lenalidomide and bortezomib, the necessity for high-dose dexamethasone has been questioned. It is noted that in the Eastern Cooperative Oncology Group trial E4A03, in which participants were randomized to receive either low-or high-dose dexamethasone in combination with lenalidomide, 1 it was the low-dose dexamethasone regimen that was associated with
